Showing results (111-120 of 143) with videos related to

Sort By:
Pageof 15
Lung Cancer (Amsterdam, Netherlands)|June 26, 2026
Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARDIsamu Okamoto, Byoung Chul Cho, Sarah B Goldberg, et al.
Clinical Lung Cancer|August 14, 2021
Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)Helena A Yu, Sarah B Goldberg, Xiuning Le, et al.
Cancer Discovery|March 6, 2026
ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer Treated with First-Line OsimertinibZofia Piotrowska, Myung-Ju Ahn, Pei Jye Voon, et al.
JCO Precision Oncology|January 16, 2018
Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung CancerJustin F Gainor, Diane Tseng, Satoshi Yoda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2020
Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)Erin M Bertino, Ryan D Gentzler, Sarah Clifford, et al.
Expert Review of Anticancer Therapy|December 20, 2022
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancerJames Chih-Hsin Yang, Caicun Zhou, Pasi A Jänne, et al.
Molecular Cancer Therapeutics|May 13, 2026
BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR MutationsYves A Millet, Alexander I Spira, Christina S Baik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2023
Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion MutationsMichael J Grant, Jacqueline V Aredo, Jacqueline H Starrett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2016
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective AnalysisJustin F Gainor, Alice T Shaw, Lecia V Sequist, et al.
JCO Precision Oncology|August 21, 2018
Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung CancerZofia Piotrowska, Mehlika Hazar-Rethinam, Coleen Rizzo, et al.
Pageof 15